{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:05:37Z","timestamp":1776081937211,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-024-04727-5","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:15:44Z","timestamp":1737778544000},"page":"3816-3826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-na\u00efve patients"],"prefix":"10.1007","volume":"50","author":[{"given":"Jurate","family":"Kemesiene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gytis","family":"Cholstauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zviniene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mantvydas","family":"Lopeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Veneviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieva","family":"Asmenaviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamile","family":"Tamosauskaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrida","family":"Pikuniene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Jievaltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"issue":"2","key":"4727_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors\u2014A Systematic Review. Eur Urol. 2023;84(2):191\u2013206. doi:https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","journal-title":"Eur Urol"},{"key":"4727_CR2","doi-asserted-by":"publisher","unstructured":"Padhani AR, Godtman RA, Schoots IG. Key learning on the promise and limitations of MRI in prostate cancer screening. Eur Radiol. Published online February 5, 2024. doi:https:\/\/doi.org\/10.1007\/s00330-024-10626-6","DOI":"10.1007\/s00330-024-10626-6"},{"key":"4727_CR3","doi-asserted-by":"publisher","unstructured":"Wenzel M, Theissen L, Preisser F, et al. Complication Rates After TRUS Guided Transrectal Systematic and MRI-Targeted Prostate Biopsies in a High-Risk Region for Antibiotic Resistances. Front Surg. 2020;7. doi:https:\/\/doi.org\/10.3389\/fsurg.2020.00007","DOI":"10.3389\/fsurg.2020.00007"},{"key":"4727_CR4","doi-asserted-by":"publisher","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine. Published online March 18, 2018. doi:https:\/\/doi.org\/10.1056\/nejmoa1801993","DOI":"10.1056\/nejmoa1801993"},{"key":"4727_CR5","unstructured":"Mottet N van den BRBECPDSMFS et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Published online 2019."},{"issue":"10","key":"4727_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.urolonc.2020.02.018","volume":"39","author":"MF Becerra","year":"2021","unstructured":"Becerra MF, Atluri VS, Bhattu AS, Punnen S. Serum and urine biomarkers for detecting clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2021;39(10):686\u2013690. doi:https:\/\/doi.org\/10.1016\/j.urolonc.2020.02.018","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"4727_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2021.10.011","volume":"524","author":"V Mugoni","year":"2022","unstructured":"Mugoni V, Ciani Y, Nardella C, Demichelis F. Circulating RNAs in prostate cancer patients. Cancer Lett. 2022;524:57\u201369. doi:https:\/\/doi.org\/10.1016\/j.canlet.2021.10.011","journal-title":"Cancer Lett"},{"key":"4727_CR8","doi-asserted-by":"publisher","unstructured":"Tomlins SA, Aubin SMJ, Siddiqui J, et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Sci Transl Med. 2011;3(94). doi:https:\/\/doi.org\/10.1126\/scitranslmed.3001970","DOI":"10.1126\/scitranslmed.3001970"},{"issue":"2","key":"4727_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/erm.10.122","volume":"11","author":"X Durand","year":"2011","unstructured":"Durand X, Moutereau S, Xylinas E, et al. Progensa\u2122 PCA3 test for prostate cancer. Expert Rev Mol Diagn. 2011;11(2):137\u201344. doi: https:\/\/doi.org\/10.1586\/erm.10.122","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"4727_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. 2016;70(1):45\u201353. doi: https:\/\/doi.org\/10.1016\/j.eururo.2015.04.039","journal-title":"Eur Urol"},{"issue":"3","key":"4727_CR11","doi-asserted-by":"publisher","first-page":"e30430","DOI":"10.2196\/30430","volume":"7","author":"A Bandala-Jacques","year":"2021","unstructured":"Bandala-Jacques A, Castellanos Esquivel KD, P\u00e9rez-Hurtado F, Hern\u00e1ndez-Silva C, Reynoso-Nover\u00f3n N. Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review. JMIR Cancer. 2021;7(3):e30430. doi:https:\/\/doi.org\/10.2196\/30430","journal-title":"JMIR Cancer"},{"issue":"2","key":"4727_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/pcan.2016.46","volume":"20","author":"M Maruf","year":"2017","unstructured":"Maruf M, Fascelli M, George AK, et al. The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI\/US fusion-guided biopsy. Prostate Cancer Prostatic Dis. 2017;20(2):179\u2013185. doi:https:\/\/doi.org\/10.1038\/pcan.2016.46","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"4727_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362\u20131367. doi:https:\/\/doi.org\/10.1016\/j.urology.2014.02.035","journal-title":"Urology"},{"issue":"3","key":"4727_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.13314","volume":"117","author":"C Poyet","year":"2016","unstructured":"Poyet C, Nieboer D, Bhindi B, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary Europe. BJU Int. 2016;117(3):401\u2013408. doi:https:\/\/doi.org\/10.1111\/bju.13314","journal-title":"BJU Int"},{"key":"4727_CR15","doi-asserted-by":"publisher","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.052","DOI":"10.1016\/j.eururo.2015.08.052"},{"issue":"3","key":"4727_CR16","doi-asserted-by":"publisher","first-page":"e2427-e2428","DOI":"10.1016\/S1569-9056(19)32142-6","volume":"18","author":"S Paliksa","year":"2019","unstructured":"Paliksa S, Gagilas J, Lopeta M, et al. Diagnostic performance of PCA3 and TMPRSS2:ERG biomarkers in prostate cancer patients urine collected with and without prostate massage. European Urology Supplements. 2019;18(3):e2427-e2428. doi:https:\/\/doi.org\/10.1016\/S1569-9056(19)32142-6","journal-title":"European Urology Supplements"},{"key":"4727_CR17","unstructured":"JSC \u201cDiagnolita\u201d. Prostate cancer biomarker test. https:\/\/www.diagnolita.lt\/en\/tests\/prostate-cancer-biomarker-test\/. Accessed 2024-03-05."},{"issue":"4","key":"4727_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.path.2022.07.008","volume":"15","author":"E Baraban","year":"2022","unstructured":"Baraban E, Epstein J. Prostate Cancer. Surg Pathol Clin. 2022;15(4):579\u2013589. doi:https:\/\/doi.org\/10.1016\/j.path.2022.07.008","journal-title":"Surg Pathol Clin"},{"key":"4727_CR19","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"issue":"6","key":"4727_CR20","doi-asserted-by":"publisher","first-page":"11347","DOI":"10.3390\/ijms140611347","volume":"14","author":"GHJM Leyten","year":"2013","unstructured":"Leyten GHJM, Wierenga EA, Sedelaar JPM, et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci. 2013;14(6):11347\u201311355. doi:https:\/\/doi.org\/10.3390\/ijms140611347","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4727_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.eururo.2012.11.014","volume":"65","author":"GHJM Leyten","year":"2014","unstructured":"Leyten GHJM, Hessels D, Jannink SA, et al. Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. Eur Urol. 2014;65(3):534\u2013542. doi:https:\/\/doi.org\/10.1016\/j.eururo.2012.11.014","journal-title":"Eur Urol"},{"issue":"4","key":"4727_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse A, Ahn J, Akbani R, et al. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011\u20131025. doi:https:\/\/doi.org\/10.1016\/j.cell.2015.10.025","journal-title":"Cell"},{"issue":"8","key":"4727_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamaoncol.2017.0177","volume":"3","author":"MG Sanda","year":"2017","unstructured":"Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol. 2017;3(8):1085. doi:https:\/\/doi.org\/10.1001\/jamaoncol.2017.0177","journal-title":"JAMA Oncol"},{"key":"4727_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.urology.2016.08.022","volume":"99","author":"M Fenstermaker","year":"2017","unstructured":"Fenstermaker M, Mendhiratta N, Bjurlin MA, et al. Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. Urology. 2017;99:174\u2013179. doi:https:\/\/doi.org\/10.1016\/j.urology.2016.08.022","journal-title":"Urology"},{"issue":"4","key":"4727_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bju.13318","volume":"118","author":"F Porpiglia","year":"2016","unstructured":"Porpiglia F, Cantiello F, De Luca S, et al. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance. BJU Int. 2016;118(4):527\u2013534. doi:https:\/\/doi.org\/10.1111\/bju.13318","journal-title":"BJU Int"},{"issue":"6","key":"4727_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/bco2.99","volume":"2","author":"JYI Tay","year":"2021","unstructured":"Tay JYI, Chow K, Gavin DJ, et al. The utility of magnetic resonance imaging in prostate cancer diagnosis in the Australian setting. BJUI Compass. 2021;2(6):377\u2013384. doi:https:\/\/doi.org\/10.1002\/bco2.99","journal-title":"BJUI Compass"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-024-04727-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T06:20:48Z","timestamp":1752646848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-024-04727-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4727"],"URL":"https:\/\/doi.org\/10.1007\/s00261-024-04727-5","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}